Cumulative drug approval applications under priority review

STO-REC-STATT2T18JT1 Official
496

China · end of 2024

Cumulative drug approval applications under priority review in China stood at 496 at end of 2024 (State Council).

Original source
Publisher
State Council
Authority tier
T1 Official
Locator
Measures facilitate approval of 48 first-in-class innovative drugs
Retrieved
17 Sep 2026
Status
Verified

What the source says

Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.

Verbatim extraction verified: The figure 496 is directly attested in the quoted passage (Measures facilitate approval of 48 first-in-class innovative drugs).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX
MLA
State Council of China. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024, https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX.
Chicago
State Council of China. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024. https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX.
BibTeX
@misc{statecouncil2024cumulative0hd2xx, author = {{State Council of China}}, title = {Measures facilitate approval of 48 first-in-class innovative drugs}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX}, note = {Original source: https://english.www.gov.cn/news/202503/20/content\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATT2T18J T1 Official

Primary Source

Publisher
State Council of China · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
Measures facilitate approval of 48 first-in-class innovative drugs
Type
Press release
Published
Locator
Measures facilitate approval of 48 first-in-class innovative drugs
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX